Medindia
Advertisement

Hypertension Drug Also Treats Multiple Sclerosis

by Shirley Johanna on March 14, 2015 at 12:56 PM

Hypertension Drug Also Treats Multiple Sclerosis
A new study revealed that guanabenz, an FDA-approved hypertension drug, prevents myelin loss and protects against clinical symptoms of multiple sclerosis (MS) in animal models. Guanabenz enhances innate cellular mechanism that protects myelin-protecting cells against inflammatory stress. Based on the findings, scientists from the University of Chicago point to promising avenues for the development of new therapeutics against MS.

"Guanabenz appears to enhance the cell's own protective machinery to diminish the loss of myelin, which is the major hallmark of MS," said Dr. Brian Popko, senior study author, Jack Miller Professor of Neurological Disorders at the University of Chicago. "While there have been many efforts to stimulate re-myelination, this now represents a unique protective approach. You don't have to repair the myelin if you don't lose it in the first place."
Advertisement

Multiple sclerosis is characterized by an abnormal immune response that leads to inflammation in the brain and the destruction of myelin Ť— a fatty sheath that protects and insulates nerve fibers. MS is thought to affect more than 2.3 million people worldwide and has no known cure.

Popko and his colleagues have previously shown that oligodendrocytes, the brain cells which produce myelin, possess an innate mechanism that responds to stressors such as inflammation. It temporarily shuts down almost all normal protein production in the cell and selectively increases the production of protective proteins. When this mechanism is malfunctioning or overloaded — by the chronic inflammation seen in MS, for example — oligodendrocyte death and demyelination is significantly increased.
Advertisement

A recent study found evidence that guanabenz, a drug approved for oral administration for hypertension, enhances this stress response pathway independent of its anti-hypertension actions. To test the suitability of guanabenz as a potential treatment for MS, Popko and his team exposed cultured oligodendrocyte cells to interferon gamma — a molecule that increases inflammation — resulting in greatly increased myelin loss and cell death.

Treating these cells with guanabenz prevented myelin loss and restored cell survival to near normal levels. Oligodendrocytes that were not exposed to interferon gamma were unaffected by guanabenz, suggesting that it enhances only an active stress response pathway.

The team then tested the drug on multiple mouse models of MS. When treated with guanabenz, mice that are genetically engineered to express high amounts of interferon gamma in their brains were protected against oligodendrocyte and myelin loss. Treated mice retained several times more myelination and oligodendrocytes than untreated mice.

To study a chronic model of MS, the researchers immunized mice with a component of myelin, triggering an immune response against myelin similar to MS in humans. Clinical symptoms developed, but guanabenz administered a week after immunization significantly delayed the onset of these symptoms and reduced peak severity. Treatment also prevented around 20 percent of mice from developing symptoms at all.

To study the suitability of guanabenz as a therapeutic after MS symptoms have already appeared and peaked, the researchers used a mouse model in which symptoms relapse and remit — cycling from high severity to low severity to high again over time. They administered guanabenz immediately after symptoms peaked, and found a nearly 50 percent reduction in severity during the next relapse cycle.

"Human MS predominantly follows a relapsing-remitting pattern," said co-author Sharon Way, PhD, a National MS Society Postdoctoral Fellow at the University of Chicago. "Our hope is that this approach would provide protection against future relapses by making them milder and less frequent."

The team confirmed that guanabenz acts by temporarily blocking the reactivation of a protein known as eukaryotic translation initiation factor 2 (eIF2α). When deactivated, eIF2α initiates the stress response pathway. Blocking its reactivation results in a prolonged stress response and provides protection against cell death. The researchers hypothesize that guanabenz stimulates a protective cascade - because fewer oligodendrocytes die, less immune cells are recruited to the brain, which results in a decreased inflammatory response and preservation of myelin levels.

The team notes that eIF2α becomes reactivated after a certain amount of time through pathways that guanabenz does not act upon, so eventually the stress response mechanism will shut down regardless of treatment. However, the protective efficacy of guanabenz and its ability to alleviate relapses, coupled with its established safety profile, makes for promising clinical implications.

The Myelin Repair Foundation, which funded this work as part of a multi-institutional effort to accelerate research and development of treatments for MS, has entered into a cooperative agreement with the National Institutes of Health to assess guanabenz as a therapeutic candidate in MS clinical studies.

"Guanabenz will probably not be a standalone drug, but we hope that it can be developed for use in combination with other medications," Popko said. Some current treatments can have severe side effects — for example dangerous infections in the brain. It would be of tremendous benefit for patients to have effective, less-risky therapies.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Lower Respiratory Tract Infections Linked to Obstructive Sleep Apnea in Children
Type 2 Diabetes can be Controlled by Unripen Green Jackfruit Flour
Covid Pandemic: How Parents can Help Kids Deal with Back-to-School Anxiety
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
High Blood Pressure Drug Toxicity Diet Lifestyle and Heart Disease Diet and High Blood Pressure Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Stress and the Gender Divide Silent Killer Diseases Quiz on Hypertension 

Recommended Reading
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or ......
Multiple Sclerosis Treatment and Modify
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity .....
Combination of Two Groups of Pulmonary Arterial Hypertension Drugs Leads to Enhanced Release of ATP by Human RBCs
A new study reports on a finding by researchers at Saint Louis University School of Medicine....
Certain Patients Not Benefited by Common Hypertension Drugs
Commonly prescribed drugs used to lower blood pressure can actually have the opposite ......
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body....
Diet and High Blood Pressure
High blood pressure or hypertension is defined as a blood pressure of above 140 mm Hg (systolic) and...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
High Blood Pressure
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it i...
Stress and the Gender Divide
Stress has become entwined in the current lifestyle of a young working couple and has resulted in th...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use